# THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

**If you are in any doubt** as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, a bank manager, solicitor, professional accountant or other professional adviser.

**If you have sold or transferred** all your shares in Xunfei Healthcare Technology Co., Ltd., you should at once hand this circular, together with the enclosed form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

讯飞医疗 Xunfei Healthcare

# Xunfei Healthcare Technology Co., Ltd.

# 訊飛醫療科技股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2506)**

## 2025 WORK REPORT OF THE BOARD OF DIRECTORS
## 2025 ANNUAL REPORT
## APPLICATION FOR COMPREHENSIVE CREDIT LINES
## 2025 FINANCIAL SETTLEMENT REPORT
## 2025 PROFIT DISTRIBUTION PLAN
## REMUNERATION PLAN FOR DIRECTORS AND SENIOR MANAGEMENT FOR 2026
## APPOINTMENT OF AUDITOR FOR 2026
## GUARANTEES FOR SUBSIDIARIES
## PROPOSED AMENDMENTS TO THE BUSINESS SCOPE OF THE COMPANY AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION
## UNCOVERED LOSSES AMOUNTING TO ONE-THIRD OF THE TOTAL PAID-UP SHARE CAPITAL
## PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES
## PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE H SHARES
## 2025 WORK REPORT OF THE INDEPENDENT NON-EXECUTIVE DIRECTORS
## AND
## NOTICE OF ANNUAL GENERAL MEETING

The notice convening the Annual General Meeting of Xunfei Healthcare Technology Co., Ltd. to be held at the Company's Meeting Room, 666 West Wangjiang Road, Shushan District, Hefei, Anhui Province, China on Friday, June 26, 2026 at 9:30 a.m. is set out on pages 33 to 37 of this circular. A form of proxy for use at the Annual General Meeting is also enclosed and published on the websites of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the Company (www.iflyhealth.com).

Whether or not you are able to attend the Annual General Meeting, please complete and sign the enclosed form of proxy in accordance with the instructions printed thereon and return it to the Company's H Share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (for H Shareholders) or the Company's head office in the PRC at No. 666 Science and Innovation Road, Chengxiqiao Community Services Center, High-tech Zone, Hefei City, Anhui Province, PRC (for Domestic Shareholders) as soon as possible but in any event not less than 24 hours before the time appointed for the Annual General Meeting (i.e. not later than 9:30 a.m. on Thursday, June 25, 2026) or any adjournment thereof. Completion and return of the form of proxy will not preclude you from attending and voting in person at the Annual General Meeting should you so wish, and in such event, the form of proxy that you have completed and returned will be deemed to be revoked.

All time and dates mentioned in this circular refer to Hong Kong time and dates.

June 5, 2026

# CONTENTS


*Page*

**Definitions** . . . . . 1

**Letter from the Board**

1. Introduction . . . . . 5
2. 2025 Work Report of the Board of Directors . . . . . 5
3. 2025 Annual Report . . . . . 5
4. Application for Comprehensive Credit Lines . . . . . 5
5. 2025 Financial Settlement Report.. . . . . 5
6. 2025 Profit Distribution Plan . . . . . 6
7. Remuneration Plan for Directors and Senior Management for 2026 . . . . . 6
8. Appointment of Auditor for 2026 . . . . . 8
9. Guarantees for Subsidiaries . . . . . 8
10. Proposed Amendments to the Business Scope of the Company and Amendments to the Articles of Association . . . . . 17
11. Uncovered Losses Amounting to One-third of the Total Paid-up Share Capital . 17
12. Proposed Granting of General Mandate to Issue Shares . . . . . 18
13. Proposed Granting of General Mandate to Repurchase H Shares . . . . . 19
14. 2025 Work Report of the Independent Non-executive Directors . . . . . 20
15. Annual General Meeting and Proxy Arrangement . . . . . 20
16. Recommendation . . . . . 21
17. Responsibility Statement . . . . . 21

# CONTENTS

**Appendix I — Proposed Amendments to the Articles of Association** . . . . . 22

**Appendix II — Explanatory Statement on the Share Repurchase Mandate** . . . . . 24

**Appendix III — 2025 Work Report of the Independent Non-executive Directors** . . 27

**Notice of Annual General Meeting** . . . . . 33

*In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:*

| | |
|---|---|
| "Annual General Meeting" | the annual general meeting of the Company to be held at the Company's Meeting Room, 666 West Wangjiang Road, Shushan District, Hefei, Anhui Province, China on Friday, June 26, 2026 at 9:30 a.m., or any adjournment thereof |
| "Articles of Association" | the articles of association of the Company currently in force |
| "Board" or "Board of Directors" | the board of Directors of the Company |
| "Company" | Xunfei Healthcare Technology Co., Ltd. (訊飛醫療科技股份有限公司), a limited liability company established under the laws of the PRC on May 13, 2016 and converted into a joint stock limited liability company in the PRC on December 24, 2021 |
| "Company Law" | the Company Law of the PRC |
| "Director(s)" | the director(s) of the Company |
| "Domestic Shareholder(s)" | holder(s) of Domestic Unlisted Shares |
| "Domestic Unlisted Share(s)" | ordinary share(s) of RMB1.00 each in the share capital of the Company, which are not listed on any stock exchange |
| "H Share(s)" | ordinary share(s) of RMB1.00 each in the share capital of the Company, which are listed on the Hong Kong Stock Exchange |
| "H Shareholder(s)" | holder(s) of H Shares |
| "HK$" or "HK dollars" | Hong Kong dollars and cents, respectively, the lawful currency of Hong Kong |
| "Hong Kong" or "HK" | the Hong Kong Special Administrative Region of the People's Republic of China |

| | |
|---|---|
| "Hong Kong Stock Exchange" or "Stock Exchange" | The Stock Exchange of Hong Kong Limited, a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited |
| "Issuance Mandate" | a general mandate proposed to be granted to the Directors to allot, issue or deal with (including sale or transfer of any Treasury Shares) additional Shares of not exceeding 20% of the total number of issued Shares (excluding any Treasury Shares) as at the date of passing of the relevant resolution |
| "Latest Practicable Date" | June 2, 2026, being the latest practicable date prior to the printing of this circular for ascertaining certain information in this circular |
| "Listing" | listing of the H Shares on the Main Board of the Hong Kong Stock Exchange |
| "Listing Rules" | the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended from time to time) |
| "PRC" or "China" | the People's Republic of China. For the purposes of this document only and except where the context requires otherwise, excludes Hong Kong, Macau and Taiwan |
| "RMB" | Renminbi, the lawful currency of the PRC |
| "SAFE" | State Administration of Foreign Exchange |
| "Share(s)" | ordinary share(s) of RMB1.00 each in the share capital of the Company, comprising Domestic Unlisted Share(s) and H Share(s) |
| "Share Repurchase Mandate" | a general mandate proposed to be granted to the Directors at the Annual General Meeting to repurchase H Shares on the Stock Exchange of not exceeding 10% of the total number of issued H Shares (excluding any Treasury Shares) as at the date of passing of the relevant resolutions |

| | |
|---|---|
| "Shareholder(s)" | holder(s) of the Share(s) |
| "Takeovers Code" | The Code on Takeovers and Mergers approved by the Securities and Futures Commission as amended from time to time |
| "Treasury Shares" | has the meaning ascribed to it in the Hong Kong Listing Rules |
| "%" | per cent |

# Xunfei Healthcare Technology Co., Ltd.
# 訊飛醫療科技股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2506)**

*Executive Director:*
Dr. TAO Xiaodong (陶曉東)

*Non-executive Directors:*
Dr. LIU Qingfeng (劉慶峰)
Mr. ZHAO Zhiwei (趙志偉)
Mr. DUAN Dawei (段大為)

*Independent Non-executive Directors:*
Prof. WANG Yang (汪揚)
Prof. ZHAO Huifang (趙惠芳)
Mr. TAN Ching (談慶)

*Head office and principal place of business in the PRC:*
4 to 5/F (North Area), No.1 Building
iFLYTEK AI Research and
Development Production Base (Phase I)
No. 666 Science and Innovation Road,
Chengxiqiao Community Services Center,
High-tech Zone
Hefei City, Anhui Province
PRC

*Principal place of business in Hong Kong:*
Room 1922, 19/F, Lee Garden One
33 Hysan Avenue, Causeway Bay
Hong Kong

June 5, 2026

*To the Shareholders*

Dear Sir/Madam,

**2025 WORK REPORT OF THE BOARD OF DIRECTORS**
**2025 ANNUAL REPORT**
**APPLICATION FOR COMPREHENSIVE CREDIT LINES**
**2025 FINANCIAL SETTLEMENT REPORT**
**2025 PROFIT DISTRIBUTION PLAN**
**REMUNERATION PLAN FOR DIRECTORS AND SENIOR MANAGEMENT FOR 2026**
**APPOINTMENT OF AUDITOR FOR 2026**
**GUARANTEES FOR SUBSIDIARIES**
**PROPOSED AMENDMENTS TO THE BUSINESS SCOPE OF THE COMPANY AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION**
**UNCOVERED LOSSES AMOUNTING TO ONE-THIRD OF THE TOTAL PAID-UP SHARE CAPITAL**
**PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES**
**PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE H SHARES**
**2025 WORK REPORT OF THE INDEPENDENT NON-EXECUTIVE DIRECTORS**
**AND**
**NOTICE OF ANNUAL GENERAL MEETING**

## 1. INTRODUCTION

The purpose of this circular is to provide the Shareholders with information in respect of certain resolutions to be proposed at the Annual General Meeting.

## 2. 2025 WORK REPORT OF THE BOARD OF DIRECTORS

An ordinary resolution will be proposed at the Annual General Meeting to consider and approve the 2025 work report of the Board of Directors (the full text of which is set out in the 2025 annual report of the Company, which is available on the websites of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the Company (https://www.iflyhealth.com)).

## 3. 2025 ANNUAL REPORT

An ordinary resolution will be proposed at the Annual General Meeting to consider and approve the 2025 annual report of the Company.

## 4. APPLICATION FOR COMPREHENSIVE CREDIT LINES

An ordinary resolution will be proposed at the Annual General Meeting to consider and approve the application to banks for comprehensive credit lines.

To meet the funding needs for daily operations and business development, the Company proposes to apply to commercial banks for a cumulative comprehensive credit line with an uncommitted credit line not exceeding RMB2.5 billion. The application for comprehensive credit lines will be valid for 12 months from the date of consideration and approval by the Annual General Meeting. During the credit period, the credit line may be utilized on a revolving basis.

## 5. 2025 FINANCIAL SETTLEMENT REPORT

An ordinary resolution will be proposed at the Annual General Meeting to consider and approve the 2025 financial settlement report of the Company, the full text of which is set out in the 2025 annual report of the Company.

## 6. 2025 PROFIT DISTRIBUTION PLAN

An ordinary resolution will be proposed at the Annual General Meeting to consider and approve the 2025 profit distribution plan of the Company.

As audited by Deloitte Touche Tohmatsu, the Company's year-end accumulated undistributed profit as of December 31, 2025 is RMB-512,310,000. The Company does not intend to distribute profits, pay cash dividends or distribute bonus shares for the year 2025. The Company will continue to actively implement its profit distribution policy in strict accordance with the requirements of relevant laws and regulations, the Articles of Association and other relevant regulations, and taking into account various factors such as the Company's stage of development, operating conditions and cash flow, to share the fruits of the Company's development with its investors and better safeguard the long-term interests of all Shareholders.

## 7. REMUNERATION PLAN FOR DIRECTORS AND SENIOR MANAGEMENT FOR 2026

An ordinary resolution will be proposed at the Annual General Meeting to consider and approve the remuneration plan for Directors and senior management of the Company for 2026.

In order to further improve the Company's incentive and discipline mechanism, effectively mobilize the work motivation and creativity of the Company's Directors and senior management, and promote the further improvement of the Company's work efficiency and operational effectiveness, the Company has formulated a remuneration plan for the Directors and senior management for 2026 in conjunction with the level of remuneration of the Directors and senior management for 2025. The plan is detailed as follows:

**(i) Target:** Directors and senior management who receive remuneration from the Company

**(ii) Remuneration Standards:**

Remuneration Plan for Directors:

The Company provides an allowance of HK$240,000 per annum to the independent Directors. Reasonable expenses, such as transportation and accommodation, incurred by external Directors and independent Directors in performing their duties (such as attending the Board of Directors' and Shareholders' Meetings of the Company) in accordance with the relevant provisions of the Company Law of the People's Republic of China and the Articles of Association shall be borne by the Company. The Company does not provide separate allowances for external Directors and

internal Directors. Internal Directors receive corresponding remuneration in accordance with the remuneration and assessment management measures corresponding to the senior management or other positions they concurrently hold.

Remuneration Plan for Senior Management:

The Company's senior management is subject to an annual salary system, and its compensation structure consists of three components, which are base salary, annual performance bonus and long-term incentives:

1. The base salary is determined in accordance with his/her position within the Company, based on the level of responsibility and competence of his/her position, and is paid on a monthly basis;

2. The annual performance bonus is based on the Company's annual business objectives and the completion of individual annual performance assessment indicators; and

3. The Company may adopt long-term incentives such as stock options, restricted shares and employee stock ownership plans for its senior management team in accordance with the operating conditions and market changes. The specific plan shall be separately determined in accordance with the relevant national laws and regulations.

**(iii) Payment Policy**

1. Basic remuneration is paid on an average monthly basis;

2. The annual salary for performance is a variable income, which is mainly determined based on the completion of the enterprise's economic benefits, the results of performance appraisal, the contribution of the employees' individual performance and their personal appraisal (if any), and is payable upon completion of the annual appraisal.

**(iv) Other Requirements**

All of the above remunerations are pre-tax amounts, and the personal income tax involved is uniformly withheld and paid by the Company. The remuneration does not include employee benefits, insurance premiums, and other compensation. The remuneration may be adjusted appropriately according to the industry conditions and the actual situation of the Company's production and operation.

## 8. APPOINTMENT OF AUDITOR FOR 2026

An ordinary resolution will be proposed at the Annual General Meeting to consider and approve the appointment of Deloitte Touche Tohmatsu as auditor of the Company for 2026, and to authorize the management to enter into an engagement contract with them for a term of one year based on the specific circumstances, and to determine their remuneration and related matters.

After discussion with Deloitte Touche Tohmatsu and taking into account, among other things, its understanding of the Group's operations, the currently expected scope of work based on the audit of the Company's consolidated financial statements for the financial year ended December 31, 2025, and on the assumption that there will be no material change in the scope of audit work for the financial year ending December 31, 2026, the estimated audit fee of Deloitte Touche Tohmatsu for its audit services for the year ending December 31, 2026 is expected to be in the range of approximately RMB3.4 million to RMB3.7 million (the "**Estimated Audit Fee**"). After due consideration of the facts and circumstances known as at the Latest Practicable Date, the Estimated Audit Fee is considered fair and reasonable.

## 9. GUARANTEES FOR SUBSIDIARIES

A special resolution will be proposed at the Annual General Meeting to consider and approve the guarantees for subsidiaries.

To better support the business development needs of its subsidiaries, the Company intends to provide guarantees for the credit facilities of a total of 6 of its holding subsidiaries whose gearing ratio exceed 70% in banks and other institutions, namely Pu'er Keda Xunfei Information Technology Co., Ltd. (普洱科大訊飛信息技術有限公司) ("**Pu'er Xunfei**"), Beijing Huiji Zhiyi Technology Co., Ltd. (北京惠及智醫科技有限公司) ("**Beijing Huiji**"), Lvliang Keda Xunfei Medical Information Technology Co., Ltd. (呂梁科大訊飛醫療信息技術有限公司) ("**Lvliang Xunfei**"), Taizhou Xunfei Medical Artificial Intelligence Healthcare Research Institute Co., Ltd. (泰州訊飛醫療人工智能研究院有限公司) ("**Taizhou Xunfei**"), Anhui Kexun Zhixie Technology Co., Ltd. (安徽科訊智械科技有限公司) ("**Kexun Zhixie**") and Zhejiang Xunyi Technology Co., Ltd. (浙江訊醫科技有限公司) ("**Zhejiang Xunyi**"). Information relating to the guarantees is set out below:

### I. Overview of Guarantees

Pu'er Keda Xunfei Information Technology Co., Ltd. (普洱科大訊飛信息技術有限公司), Beijing Huiji Zhiyi Technology Co., Ltd. (北京惠及智醫科技有限公司), Lvliang Keda Xunfei Medical Information Technology Co., Ltd. (呂梁科大訊飛醫療信息技術有限公司), Taizhou Xunfei Medical Artificial Intelligence Healthcare Research Institute Co., Ltd. (泰州

訊飛醫療人工智能研究院有限公司), Anhui Kexun Zhixie Technology Co., Ltd. (安徽科訊智械科技有限公司) and Zhejiang Xunyi Technology Co., Ltd. (浙江訊醫科技有限公司) are holding subsidiaries of the Company. The Company directly or indirectly holds 100%, 75%, 90%, 95%, 100% and 100% of their equity interests, respectively, and none of them are judgment defaulters.

In the next 12 months, the Company expects to provide a total guarantee amount of RMB50 million or its equivalent in foreign currency for the above-mentioned wholly-owned and holding subsidiaries. Specifically, this includes providing guarantees of no more than RMB10 million each for Pu'er Xunfei, Beijing Huiji, Lvliang Xunfei, and Taizhou Xunfei, no more than RMB5 million each for Kexun Zhixie and Zhejiang Xunyi. The above guarantees are general guarantees or joint and several liability guarantees. The guarantee limit is valid for 12 months from the date of approval by the general meeting and can be utilized on a revolving basis within the limit. Within the total limit, the Company may reallocate the limits among the qualified guaranteed parties according to the actual needs of each subsidiary.

The Company's wholly-owned and holding subsidiaries will, in due course, apply for credit facilities from partner institutions (including but not limited to banks, non-bank financial institutions and other business partners) according to the actual needs of their production, operation and business expansion. The forms of the above credit facilities include but are not limited to working capital loans, fixed asset loans, project loans, bank acceptance bills, commercial acceptance bills, letters of guarantee, factoring (including supply chain type), and trade finance business, etc. The specific credit amount, credit term, and credit type are subject to the actual approval of the financial institutions.

## II. Basic Information of the Guaranteed Person

### *1. Name: Lvliang Keda Xunfei Medical Information Technology Co., Ltd. (呂梁科大訊飛醫療信息技術有限公司)*

| | |
|---|---|
| Date of Establishment: | December 1, 2021 |
| Place of Registration: | 3/F, Smart City Operation Center, Digital Economy Industrial Park, Lvliang Economic Development Zone, Tianjiahui Street, Lishi District, Lvliang City, Shanxi Province |
| Legal Representative: | Yin Dahai (尹大海) |
| Registered Capital: | RMB60 million |

| | |
|---|---|
| Company Type: | Limited liability company (invested or controlled by natural persons) |
| Scope of Business: | General Business: IoT technology services; AI foundation software development; network and information security software development; information technology consulting services; AI public service platform technical consultation services; information system operation and maintenance services; information system integration services; technical services, technical development, technical consultation, technical exchange, technical transfer, technical promotion; project management services (Except for items subject to statutory approval, the company may autonomously conduct business activities under its business license in accordance with the law) |

*2. Name: Pu'er Keda Xunfei Information Technology Co., Ltd. (普洱科大訊飛信息技術有限公司)*

| | |
|---|---|
| Date of Establishment: | June 9, 2022 |
| Place of Registration: | Room 401, 4/F, Pu'er College Entrepreneurship Public Training Base, No. 6 Xueyuan Road, Simao District, Pu'er City, Yunnan Province |
| Legal Representative: | Yin Dahai (尹大海) |
| Registered Capital: | RMB50 million |
| Company Type: | Limited liability company (sole proprietorship of legal persons not invested or controlled by natural persons) |

| | |
|---|---|
| Scope of Business: | General Business: software development; information technology consulting services; Internet of Things (IoT) technology services; information system integration services; network and information security software development; artificial intelligence (AI) public service platform technical consultation services; AI public data platform; AI infrastructure resources and technology platform; big data services; AI foundation software development; AI application software development; AI theory and algorithmic software development; AI general application system; AI industry application system integration services; information system operation and maintenance services (Except for items subject to statutory approval, the company may autonomously conduct business activities under its business license in accordance with the law) |

*3. Name: Beijing Huiji Zhiyi Technology Co., Ltd. (北京惠及智醫科技有限公司)*

| | |
|---|---|
| Date of Establishment: | June 5, 2020 |
| Place of Registration: | Room 301, 3/F, Building 7, No. 8 Dongbeiwang West Road, Haidian District, Beijing |
| Legal Representative: | Li Lei (李磊) |
| Registered Capital: | RMB20.28 million |
| Company Type: | Other limited liability company |

Scope of Business: Technology development, technology consulting, technology services, technology promotion, technology transfer; medical research and experimental development; sales of Class I and II medical devices, computers, software and auxiliary equipment, and communication equipment; computer system services; information system integration services; data processing (except for bank card centres in data processing and cloud computing data centres with a PUE of 1.5 or more); basic software services, application software services; health management, health counselling (except for diagnosis and treatment activities subject to approval); design, production, agency and distribution of advertisements; manufacture of Class II and Class III medical devices; Class III medical device sales; Internet information services (Market players may autonomously choose their own business items and conduct business activities in accordance with the law. For the manufacture of Class II and Class III medical devices and sales of Class III medical devices, Internet information services and other items subject to statutory approval, business activities may be conducted in accordance with the consent given by relevant departments. (The company shall not engage in the business activities prohibited and restricted by the state and the city's industrial policy)

4. ***Name: Taizhou Xunfei Medical Artificial Intelligence Healthcare Research Institute Co., Ltd. (泰州訊飛醫療人工智能研究院有限公司)***

Date of Establishment: December 11, 2023

| | |
|---|---|
| Place of Registration: | Room 1501, Block D, Data Building, No. 799-4, Yaocheng Avenue, Taizhou Pharmaceutical High-tech Industrial Development Zone, Taizhou City, Jiangsu Province |
| Legal Representative: | Yin Dahai (尹大海) |
| Registered Capital: | RMB30 million |
| Company Type: | Limited liability company |
| Scope of Business: | Licensed Business: Class III medical device business; Class III medical device manufacturing; Class II medical device manufacturing; Internet hospital services that rely on physical hospitals (Items subject to approval by law may only be carried out after approval by the relevant departments. Specific business activities are subject to the approval results). General Business: sales of Class II medical devices; software development; technical services, technical development, technical consultation, technical exchange, technical transfer, technical promotion; AI hardware sales; AI application software development; AI public service platform technical consultation services; AI theory and algorithm software development; AI foundation software development; AI industry application system integration services; AI general application system; information system integration services; remote health management services; smart home consumer devices sales; information technology consulting services (Except for items subject to statutory approval, the company may autonomously conduct business activities under its business license in accordance with the law) |

*5. Name: Zhejiang Xunyi Technology Co., Ltd. (浙江訊醫科技有限公司)*

| | |
|---|---|
| Date of Establishment: | August 19, 2024 |
| Place of Registration: | Room 909, 9/F, Building 3, Intelligent Vision Industrial Park, No. 9 Xingnong Road, Jiyang Street, Zhuji City, Zhejiang Province |
| Legal Representative: | Yin Dahai (尹大海) |
| Registered Capital: | RMB10 million |
| Company Type: | Limited liability company (sole proprietorship of legal persons not invested or controlled by natural persons) |
| Scope of Business: | General Business: software development; technical services, technical development, technical consultation, technical exchange, technical transfer, technical promotion; AI hardware sales; AI application software development; AI public service platform technical consultation services; AI theory and algorithm software development; AI foundation software development; AI industry application system integration services; AI general application system; information system integration services; remote health management services; smart home consumer devices sales; information technology consulting services; Class II medical devices sales (Except for items subject to statutory approval, the company may autonomously conduct business activities under its business license in accordance with the law). Licensed Business: Class III medical device business; Class III medical device manufacturing; Class II medical device manufacturing; Internet hospital services that rely on physical hospitals (Items subject to approval by law may only be carried out after approval by the relevant departments. Specific business activities are subject to the approval results) |

*6. Name: Anhui Kexun Zhixie Technology Co., Ltd. (安徽科訊智械科技有限公司)*

| | |
|---|---|
| Date of Establishment: | May 20, 2025 |
| Place of Registration: | Room 459, 4/F, No. 1 Building, iFLYTEK AI Research and Development Production Base (Phase I), No. 666 Science and Innovation Road, Chengxiqiao Community Services Center, High-tech Zone, Hefei City, Anhui Province |
| Legal Representative: | Cui Rongtao (崔榮濤) |
| Registered Capital: | RMB10 million |
| Company Type: | Limited liability company (sole proprietorship of legal persons not invested or controlled by natural persons) |

| | |
|---|---|
| Scope of Business: | General Business: technical services, technical development, technical consultation, technical exchange, technical transfer, technical promotion; software development; information technology consulting services; sales of internet equipment; repair of computers and office equipment; manufacturing of office equipment consumables; retail of computer software, hardware and auxiliary equipment; computer system services; manufacturing of computer software, hardware and peripheral equipment; leasing services (excluding licensed leasing services); property management; domestic trade agency; Class II medical device sales; leasing of non-residential real estate; photography and video production services; graphic design; technology import and export; import and export agency; Class I medical device sales; import and export of goods; information consulting services (excluding licensed information consulting services); retail of daily-use home appliances; sales of household appliances; sales of household appliance spare parts; sales of electrical accessories; sales of general merchandise; research and development of household appliances; internet sales (excluding sales of goods requiring a license) (In addition to the licensed business, the company may autonomously conduct non-prohibited or restricted business in accordance with laws and regulations). Licensed Business: Class II medical device manufacturing; Class III medical device manufacturing; Class III medical device business; online cultural business; Class I value-added telecommunications business; Class II value-added telecommunications business (Items subject to approval by law may only be carried out after approval by the relevant departments. Specific business activities are subject to the approval documents or licenses of relevant departments) |

## 10. PROPOSED AMENDMENTS TO THE BUSINESS SCOPE OF THE COMPANY AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

A special resolution will be proposed at the Annual General Meeting to consider and approve the amendments to the business scope of the Company and amendments to the Articles of Association.

Based on the actual business needs of the Company, the Company now proposes to change its business scope as follows:

Upon registration in accordance with the law, the Company's business scope is: General items: Class II medical devices sales; software development; technical services, technical development, technical consultation, technical exchange, technical transfer, technical promotion; AI hardware sales; AI application software development; AI public service platform technical consultation services; AI theory and algorithm software development; AI foundation software development; AI industry application system integration services; AI general application system; information system integration services; remote health management services; smart home consumer devices sales; information technology consulting services (In addition to the licensed business, the Company may autonomously conduct non-prohibited or restricted business in accordance with laws and regulations) Licensed items: Class III medical device business; Class III medical device manufacturing; Class II medical device manufacturing; health consultation services (excluding diagnosis and treatment services); Class I medical device sales; sales of health food (pre-packaged); food sales; sales of sanitary products and disposable medical supplies; advertising publishing; advertising design and agency; advertising production; internet information services, Class II value-added telecom services, internet information services for pharmaceuticals, internet information services for medical devices, sales of special medical purpose formula foods, sales of infant formula milk powder and other infant formula foods; physical hospital-based internet hospital services (projects subject to approval by law can only be carried out after approval by the relevant departments).

At the same time, the specific amendments to the Articles of Association proposed by the Company in respect of the foregoing matters are set out in Appendix I to this circular.

## 11. UNCOVERED LOSSES AMOUNTING TO ONE-THIRD OF THE TOTAL PAID-UP SHARE CAPITAL

An ordinary resolution will be proposed at the Annual General Meeting to consider and approve the matters in relation to uncovered losses amounting to one-third of the total paid-up share capital.

As audited by Deloitte Touche Tohmatsu, the undistributed profits of the Company amounted to RMB-512,310,000 as at December 31, 2025, and the paid-up share capital of the Company amounted to RMB120,880,000, and the amount of the uncovered losses had exceeded one-third of the total paid-up share capital.

The main reasons for the Company's uncovered losses were as follows:

To maintain its leadership in core technologies and continuously enrich its product matrix, the Company has been continuously investing in high-intensity research and development, with an average R&D expenditure (excluding amortization of options) as a percentage of revenue amounting to 36% from 2021 to 2025.

To motivate the management team and the core cadre, the Company launched an equity incentive plan in September 2021. The amortization of equity incentive cost from 2021 to 2025 amounted to RMB301,960,000 in aggregate.

In view of the Company's current operating conditions, the Company will actively carry out the following tasks to enhance its profitability:

1. Continuously strengthen our investment in AI technology and optimize and upgrade our existing products and services to enrich our product portfolio and expand the application scenarios of our products and services, so as to steadily increase our market share and maintain our leading position. At the same time, the Company will enhance its operational efficiency and improve cost control to achieve continuous improvement in profitability.

2. Capture new profit opportunities through commercialization synergies to further expand hospital services, regional healthcare solutions and patient services to increase and diversify revenues.

3. Enlarge geographic coverage and customer base, expand and enhance cooperation with existing PHC institutions and hospital customers through diversification of the solution matrix, consolidate cooperative relationships with existing customers, increase revenue from single-customer transactions, and actively secure new customers.

## 12. PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES

In order to give the Company the flexibility to issue Shares if and when appropriate, a special resolution will be proposed at the Annual General Meeting to approve the granting of the Issuance Mandate to the Directors to allot, issue or deal with (including sale or transfer of any Treasury Shares) additional Shares of not exceeding 20% of the total number of issued Shares (excluding any Treasury Shares) as at the date of passing of such resolution. As at the Latest Practicable Date, there were 120,878,233 Shares in issue, including 43,581,121 Domestic Unlisted Shares and 77,297,112 H Shares. Subject to the passing of the resolution related to the granting of the Issuance Mandate and on the basis that the issued share capital of the Company remains unchanged on the date of the Annual General Meeting, the Company will be allowed to allot and issue (including sale or transfer of any Treasury Shares) a maximum of 24,175,646 Shares in accordance with the Issuance Mandate.

## 13. PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE H SHARES

The Company Law provides that a joint stock limited company incorporated in the PRC may not purchase its own shares except under any of the following circumstances: (1) reducing the registered capital of the company; (2) merging with another company that holds its shares; (3) using shares for the employee stock ownership plan or as equity incentives; (4) a shareholder requesting the company to purchase its shares held by him/her since he/she objects to a resolution of the shareholders' general meeting on the combination or division of the company; (5) using shares for converting corporate bonds issued by the listed company that are convertible into shares; and (6) it is necessary for a listed company to protect its corporate value and the rights and interests of shareholders.

Such mandate is required to be given by way of a special resolution passed by shareholders in general meeting.

As H Shares are traded on the Stock Exchange in HK dollars and the price payable by the Company upon any repurchase of H Shares will, therefore, be paid in HK dollars, the payment of the repurchase price is subject to the approval of SAFE or entities authorized by it.

The Company will cancel any repurchased Shares and/or hold the repurchased Shares as Treasury Shares based on the circumstances at the time of repurchasing the Shares (such as market conditions and its capital management needs). If the Company intends to cancel any repurchased Shares, in accordance with the requirements of the Articles of Association of the Company applicable to capital reduction, the Company will have to notify its creditors within 10 days from the date of the Company's resolution on reduction of registered capital and shall publish an announcement on the newspapers (or on the National Enterprise Credit Information Publicity System) and the website of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) within 30 days from the date of such resolution. The creditors may, within 30 days after receiving such notice or, for those who do not receive the notice, within 45 days from the date of the announcement, demand the Company to settle their debts or provide corresponding guarantees for such debts.

In order to provide more flexibility to the Directors to repurchase H Shares if and when appropriate, a special resolution will be proposed at the Annual General Meeting to approve the granting of the Share Repurchase Mandate to the Directors to repurchase H Shares on the Stock Exchange of not exceeding 10% of the total number of issued H Shares (excluding any Treasury Shares) as at the date of passing of such resolution.

An explanatory statement required by the Listing Rules to provide the Shareholders with requisite information reasonably necessary for them to make an informed decision on whether to vote for or against the granting of the Share Repurchase Mandate is set out in Appendix II to this circular.

## 14. 2025 WORK REPORT OF THE INDEPENDENT NON-EXECUTIVE DIRECTORS

Shareholders will also listen to the 2025 Work Report of the Independent Non-executive Directors at the Annual General Meeting. The full text of the report is included in Appendix III of this circular.

## 15. ANNUAL GENERAL MEETING AND PROXY ARRANGEMENT

The notice of the Annual General Meeting is set out on pages 33 to 37 of this circular.

Pursuant to the Listing Rules, any vote of Shareholders at a general meeting must be taken by poll except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands. An announcement on the poll results will be published by the Company after the Annual General Meeting in the manner prescribed under the Listing Rules.

The record date for determining the entitlement to attend and vote at the Annual General Meeting is Friday, June 26, 2026. For the purpose of determining the identity of the holders of H Shares entitled to attend and vote at the Annual General Meeting, the register of members of the Company will be closed from Tuesday, June 23, 2026 to Friday, June 26, 2026, both dates inclusive, during which period no transfer of H Shares will be registered. In order to be eligible to attend and vote at the Annual General Meeting, unregistered holders of H Shares of the Company shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company's H Share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration not later than 4:30 p.m. (Hong Kong time) on Monday, June 22, 2026, being the last registration date.

The form of proxy for use at the Annual General Meeting is enclosed with this circular and such form of proxy is also published on the websites of Hong Kong Exchanges and Clearing Limited (http://www.hkexnews.hk) and the Company (www.iflyhealth.com). To be valid, the form of proxy must be completed and signed in accordance with the instructions printed thereon and deposited, together with the power of attorney or other authority (if any) under which it is signed or a notarized copy of that power of attorney or authority, at the Company's H Share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (for H Shareholders) or the Company's head office in the PRC at No. 666 Science and Innovation Road, Chengxiqiao Community Services Center, High-tech Zone, Hefei City, Anhui Province, PRC (for Domestic Shareholders) as soon as possible but in any event not less than 24 hours before the time appointed for the Annual General Meeting (i.e. not later than 9:30 a.m. on Thursday, June 25, 2026) or any adjournment thereof. Completion and delivery of the form of proxy will not preclude you from attending and voting at the Annual General Meeting or any adjourned meeting should you so wish, and in such event, the form of proxy that you have completed and returned will be deemed to be revoked.

## 16. RECOMMENDATION

The Directors consider that all the resolutions as set out in the notice of the Annual General Meeting are in the best interests of the Company and the Shareholders. Accordingly, the Directors recommend the Shareholders to vote in favour of all the resolutions to be proposed at the Annual General Meeting.

## 17. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters in the omission of which would make any statement herein or this circular misleading.

Yours faithfully,
By order of the Board
**Xunfei Healthcare Technology Co., Ltd.**
**Dr. Tao Xiaodong**
*Executive Director*

The Company proposes to amend the Articles of Association in connection with the revision of its business scope as follows:

| Article Number | Original Content | Amended Content |
|---|---|---|
| Article 15 | Registered in accordance with the law, the Company's business scope is: General business — sales of Class II medical devices; software development; technical services, technology development, technical consulting, technical exchanges, technology transfer, technology promotion; sales of AI hardware; AI application software development; AI public service platform technical consulting services; AI theory and algorithms software development; AI basic software development; AI industry application system integration services; AI general application systems; information system integration services; remote health management services; sales of smart home consumer equipment; information technology consulting services (in addition to approved business, we can independently operate businesses that are not prohibited or restricted by laws and regulations in accordance with the laws). Licensed business Class III medical device business; Class III medical device production; Class II medical device production; health consultation services (excluding medical treatment services); sales of Class I medical devices; sales of health food (pre-packaged); sales of food; sales of sanitary products and disposable medical supplies; advertising publishing; advertising design and agency; advertising production; internet information services, Class II value-added telecom services, internet information services for pharmaceuticals, internet information services for medical devices, sales of special medical purpose formula foods, sales of infant formula milk powder and other infant formula foods; physical hospital-based internet hospital services (projects subject to approval by law can only be carried out after approval by the relevant departments). | Registered in accordance with the law, the Company's business scope is: General business — sales of Class II medical devices; software development; technical services, technology development, technical consulting, technical exchanges, technology transfer, technology promotion; sales of AI hardware; AI application software development; AI public service platform technical consulting services; AI theory and algorithms software development; AI basic software development; AI industry application system integration services; AI general application systems; information system integration services; remote health management services; sales of smart home consumer equipment; information technology consulting services (in addition to approved business, we can independently operate businesses that are not prohibited or restricted by laws and regulations in accordance with the laws). Licensed business Class III medical device business; Class III medical device production; Class II medical device production; health consultation services (excluding medical treatment services); sales of Class I medical devices; sales of health food (pre-packaged); sales of food; sales of sanitary products and disposable medical supplies; advertising publishing; advertising design and agency; advertising production; internet information services, ~~Class II value-added telecom services,~~ internet information services for pharmaceuticals, internet information services for medical devices, sales of special medical purpose formula foods, sales of infant formula milk powder and other infant formula foods; physical hospital-based internet hospital services (projects subject to approval by law can only be carried out after approval by the relevant departments). |

| Article Number | Original Content | Amended Content |
|---|---|---|
| Article 80 | The following matters shall be passed by way of an ordinary resolution at the general meeting:<br><br>(1) work report of the Board of Directors;<br><br>(2) the profit distribution plans, and loss compensation plans drawn up by the Board of Directors;<br><br>(3) the appointment and removal of members of the Board of Directors and the Board of Supervisors who are not represented by employee representatives, and the remuneration and payment methods of members of the Board of Directors and the Board of Supervisors;<br><br>(4) the Company's annual budgets and final accounts;<br><br>(5) the annual report of the Company;<br><br>(6) matters other than those required by laws, administrative regulations, the securities regulatory rules of the place where the Shares of the Company are listed or the Articles of Association to be passed by way of a special resolution. | The following matters shall be passed by way of an ordinary resolution at the general meeting:<br><br>(1) work report of the Board of Directors;<br><br>(2) the profit distribution plans, and loss compensation plans drawn up by the Board of Directors;<br><br>(3) the appointment and removal of members of the Board of Directors ~~and the Board of Supervisors~~ who are not represented by employee representatives, and the remuneration and payment methods of members of the Board of Directors ~~and the Board of Supervisors~~;<br><br>(4) the Company's annual ~~budgets and~~ final accounts;<br><br>(5) the annual report of the Company;<br><br>(6) matters other than those required by laws, administrative regulations, the securities regulatory rules of the place where the Shares of the Company are listed or the Articles of Association to be passed by way of a special resolution. |

The following is an explanatory statement required by the Listing Rules to provide the Shareholders with requisite information reasonably necessary for them to make an informed decision on whether to vote for or against the special resolution to be proposed at the Annual General Meeting in relation to the granting of the Share Repurchase Mandate.

## 1. REGISTERED CAPITAL

As at the Latest Practicable Date, the registered capital of the Company was RMB120,878,233, comprising 43,581,121 Domestic Unlisted Shares and 77,297,112 H Shares of RMB1.00 each.

Subject to the passing of the special resolution in respect of the granting of the Share Repurchase Mandate at the Annual General Meeting and on the basis that the issued share capital of the Company remains unchanged on the date of the Annual General Meeting, i.e. being 43,581,121 Domestic Unlisted Shares and 77,297,112 H Shares, the Directors will be authorized under the Share Repurchase Mandate to repurchase, during the period in which the Share Repurchase Mandate remains in force, a total of 7,729,711 H Shares, representing 10% of the total number of H Shares in issue (excluding any Treasury Shares) as at the date of the Annual General Meeting.

## 2. REASONS FOR SHARE REPURCHASE

The Directors believe that the granting of the Share Repurchase Mandate is in the best interests of the Company and the Shareholders. Such repurchase may, depending on the market conditions and funding arrangements at the time, lead to an enhancement of the net asset value per Share and/or earnings per Share and will only be made when the Directors believe that such repurchase will benefit the Company and the Shareholders.

## 3. FUNDING OF SHARE REPURCHASE

The Company may only apply funds legally available for share repurchase in accordance with its Articles of Association, the laws of the PRC and/or any other applicable laws, as the case may be.

## 4. IMPACT OF SHARE REPURCHASE

There might be a material adverse impact on the working capital or gearing position of the Company (as compared with the position disclosed in the audited accounts contained in the annual report of the Company for the year ended December 31, 2025) in the event that the Share Repurchase Mandate was to be carried out in full at any time during the proposed repurchase

period. However, the Directors do not intend to exercise the Share Repurchase Mandate to such extent as would, in the circumstances, have a material adverse effect on the working capital requirements of the Company or the gearing levels which in the opinion of the Directors are from time to time appropriate for the Company.

The Company will cancel any repurchased Shares and/or hold the repurchased Shares as Treasury Shares based on the circumstances at the time of repurchasing the Shares (such as market conditions and its capital management needs).

## 5. MARKET PRICES OF H SHARES

The highest and lowest prices at which the H Shares have been traded on the Stock Exchange during each of the previous 12 months up to and including the Latest Practicable Date were as follows:

| **Month** | **Highest** | **Lowest** |
|---|---|---|
| | *HK$* | *HK$* |
| **2025** | | |
| June | 128.00 | 94.00 |
| July | 119.50 | 98.75 |
| August | 121.00 | 98.80 |
| September | 113.50 | 100.50 |
| October | 105.50 | 84.50 |
| November | 89.15 | 80.30 |
| December | 95.65 | 70.15 |
| **2026** | | |
| January | 114.70 | 75.80 |
| February | 95.00 | 79.70 |
| March | 81.70 | 64.40 |
| April | 73.65 | 64.55 |
| May | 89.40 | 70.15 |
| June (as of the Latest Practicable Date) | 85.20 | 81.95 |

## 6. GENERAL

To the best of their knowledge and having made all reasonable enquiries, none of the Directors nor any of their respective close associates (as defined in the Listing Rules) have any present intention to sell any H Shares to the Company in the event that the granting of the Share Repurchase Mandate is approved by the Shareholders.

The Company has not been notified by any core connected persons (as defined in the Listing Rules) of the Company that they have a present intention to sell any H Shares to the Company, or that they have undertaken not to sell any H Shares held by them to the Company in the event that the granting of the Share Repurchase Mandate is approved by the Shareholders.

The Directors will exercise the power of the Company to make repurchases pursuant to the Share Repurchase Mandate in accordance with the Listing Rules and the applicable laws and regulations of the PRC. To the best of the Directors' knowledge, there is nothing unusual in this Explanatory Statement and the Share Repurchase Mandate.

## 7. TAKEOVERS CODE

If as a result of a repurchase of H Shares pursuant to the Share Repurchase Mandate, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition of voting rights for the purposes of the Takeovers Code. Accordingly, a Shareholder or a group of Shareholders acting in concert (within the meaning under the Takeovers Code), depending on the level of increase in the Shareholder's interest, could obtain or consolidate control of the Company and thereby become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code.

To the best of the Company's knowledge, as at the Latest Practicable Date, iFlytek Co., Ltd. was interested in 60,733,695 Shares representing approximately 50.24% of the total issued share capital of the Company. In the event that the Directors exercise the proposed Share Repurchase Mandate in full, the aggregate shareholding of iFlytek Co., Ltd. would be increased to approximately 54% of the issued share capital of the Company. The Directors consider that such increase in shareholding would give rise to an obligation to make a mandatory offer under Rule 26 of the Takeovers Code.

The Directors do not propose to exercise the Share Repurchase Mandate to such an extent as would, in the circumstances, give rise to an obligation to make a mandatory offer in accordance with Rule 26 of the Takeovers Code and/or result in the aggregate number of Shares held by the public shareholders falling below the prescribed minimum percentage required by the Stock Exchange.

## 8. SHARE REPURCHASE MADE BY THE COMPANY

During the 6 months prior to the Latest Practicable Date, the Company had not repurchased any of the Shares (whether on the Stock Exchange or otherwise).

In 2025, as independent non-executive Directors of Xunfei Healthcare Technology Co., Ltd. (the "**Company**"), we have diligently and dutifully performed our duties as independent directors in strict accordance with the provisions and requirements of the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, and the Company's Articles of Association and Working System for Independent Directors. We have exercised our relevant powers independently and responsibly, paid attention to the Company's development, and fully played the role of independent directors. Each independent non-executive Director has signed a confirmation letter confirming his/her annual independence pursuant to Rule 3.13 of the Listing Rules, thereby safeguarding the interests of the Company and its shareholders, particularly public shareholders. A summary of the principal activities during 2025 is set out below:

## I. BASIC INFORMATION ON INDEPENDENT NON-EXECUTIVE DIRECTORS

The Company's second-session Board of Directors comprises 7 directors, including 3 independent non-executive Directors. The number of independent non-executive Directors is no fewer than 3 and accounts for at least one-third of the total Board membership. They possess appropriate professional qualifications, with at least 1 having appropriate accounting or relevant financial management expertise. Additionally, 1 independent non-executive Director is permanently resident in Hong Kong, ensuring compliance with applicable laws, regulations, and the Articles of Association.

Wang Yang (汪揚), male, aged 62, is our independent non-executive Director. Prof. Wang was appointed as our independent non-executive Director on August 12, 2024 with effect from December 6, 2024. Prof. Wang Yang is a professor in the Department of Mathematics, specializing in blockchain research, data science and applied mathematics. Prof. Wang currently serves as Vice-President for Institutional Advancement and Chair Professor of Mathematics, Computing and Data Science at The University of Hong Kong. He joined the Hong Kong University of Science and Technology in 2014 as a Chair Professor, and has held positions including Head of the Department of Mathematics, Dean of the School of Science, and Vice-President for Institutional Advancement. Prof. Wang was also appointed as an independent non-executive director of Antalpha Platform Holding Company (listed on the Nasdaq Stock Exchange under the stock code of ANTA) in May 2025, and as an independent non-executive director of Solowin Holdings (listed on the Nasdaq Stock Exchange under the stock code of AXG) in October 2025. His other previous working experience includes consecutively serving as an assistant professor, an associate professor and a professor in mathematics, an adjunct professor of The Logistics Institute, an undergraduate director of the School of Mathematics, and an associate chair of the School of Mathematics at Georgia Institute of Technology from July 1989 to May 2007, serving as the department chair of Mathematics at Michigan State University from August 2007 to August 2014, and serving as a program director at the United States National Science Foundation from September 2006 to August 2007. Prof. Wang obtained his bachelor's degree in mathematics from the University of Science

and Technology of China (中國科學技術大學) in the PRC in July 1983, and his Master of Science degree and Doctorate of Philosophy degree in mathematics from Harvard University in the United States in June 1988 and March 1990, respectively.

Zhao Huifang (趙惠芳), female, aged 73, is our independent non-executive Director. Prof. Zhao was appointed as our independent non-executive Director on January 25, 2024. Prof. Zhao has over 40 years of experience in accounting and financial management. Since July 1977, she has been with Hefei University of Technology (合肥工業大學), where she consecutively served as a teaching assistant in economics for six years, lecturer, associate professor and professor in accounting for over 40 years. In addition, Prof. Zhao has also consecutively served as deputy dean, dean and secretary of the party committee of the school of management of Hefei University of Technology from June 1990 to February 2011, the director of MBA/MPA management centre of Hefei University of Technology from May 2007 to February 2014, and the director of institute of financial management of Hefei University of Technology from July 2007 to February 2017. Prof. Zhao has abundant working experience as a director and member/chairwoman of the audit committee of listed companies, including serving as: (i) an independent non-executive director and a member and the chairwoman of the audit committee of Anhui Wenergy Company Limited. (安徽皖能股份有限公司, a company listed on the Shenzhen Stock Exchange under the stock code of 000543) from June 2003 to May 2009; (ii) an independent non-executive director of Anhui Huilong Agricultural Means of Production Co., Ltd. (安徽輝隆農資股份有限公司, a company listed on the Shenzhen Stock Exchange under the stock code of 002556) from November 2009 to February 2015 and the chairwoman of its audit committee from December 2011 to February 2015; (iii) an independent non-executive director and the chairwoman of the audit committee of Anhui Jianghuai Automobile Group Co., Ltd. (安徽江淮汽車股份有限公司, a company listed on the Shanghai Stock Exchange under the stock code of 600418) from March 2009 to July 2015; (iv) an independent non-executive director of Hefei Urban Construction Development Co., Ltd. (合肥城建股份有限公司, a company listed on the Shenzhen Stock Exchange under the stock code of 002208) from January 2009 to September 2015 and the chairwoman of its audit committee from February 2012 to September 2015; (v) an independent non-executive director of Hua'an Securities Co., Ltd. (華安證券股份有限公司, a company listed on the Shanghai Stock Exchange under the stock code of 600909) from January 2013 to May 2019 and a member of its audit committee from March 2016 to April 2019; (vi) an independent non-executive director of Anhui Ankai Automobile Co., Ltd. (安徽安凱汽車股份有限公司, a company listed on the Shenzhen Stock Exchange under the stock code of 000868) from November 2015 to March 2022 and the chairwoman of its audit committee from October 2016 to March 2022; (vii) an independent non-executive director and a member of the audit committee of Time Publishing and Media Co., Ltd. (時代出版傳媒股份有限公司, a company listed on the Shanghai Stock Exchange under the stock code of 600551) from November 2015 to January 2023; (viii) an independent non-executive director and the chairwoman of the audit committee of iFlytek Co., Ltd. (科大訊飛股份有限公司, a company listed on the Shenzhen Stock Exchange under the stock code of 002230) from January 2017 to January 2023;

(ix) an independent non-executive director and a member of the audit committee of Weichai Power Co., Ltd. (濰柴動力股份有限公司, a company listed on the Hong Kong Stock Exchange under the stock code of 2338 and Shenzhen Stock Exchange under the stock code of 000338) from June 2020 to June 2023; (x) an independent non-executive director and a member of the audit committee of Anhui Gourgen Traffic Construction Co., Ltd. (安徽交通建設股份有限公司, a company listed on the Shanghai Stock Exchange under the stock code of 603815) since April 2023; (xi) an independent non-executive director and a member of the audit committee of Sinomach General Machinery Science & Technology Co., Ltd. (國機通用機械科技股份有限公司, a company listed on the Shanghai Stock Exchange under the stock code of 600444) from September 2019 to December 2025; and (xii) an independent non-executive director and a member of the audit committee of Anhui Anli Material Technology Co., Ltd. (安徽安利材料科技股份有限公司), a company listed on the Shenzhen Stock Exchange, stock code: 300218) since April 2024. Prof. Zhao was granted a number of awards in the areas including accounting and financial management. The "Corporate Accounting" (《企業會計學》) of which she acted as editor-in-chief was granted the second prize for "Excellent Higher Education Textbooks" (全國普通高等學校優秀教材) by Ministry of Education of the People's Republic of China (中華人民共和國教育部) in October 2002 and her project named "Study on the Knowledge System of Management Professional Finance (Non-accounting) and Accounting" (管理類(非會計)專業財務與會計知識體系研究) was granted the first prize of "Anhui Provincial Outstanding Teaching Achievement Award" (安徽省優秀教學成果) by Department of Education of Anhui Province (安徽省教育廳) in March 2005. In addition, Prof. Zhao was granted the "Special Government Allowances" (安徽省政府特殊津貼) by Anhui Municipal People's Government (安徽省人民政府) in July 2008. Prof. Zhao graduated in political theory from Hefei University of Technology (合肥工業大學) in the PRC in August 1977, engaged in advanced study of economics in Nanjing University (南京大學) in the PRC from September 1979 to July 1980, and completed study in teaching assistant program of Anhui University (安徽大學) focusing on economics in the PRC in November 1986, and she conducted collaborative research in accounting at the faculty of business of Kurume University in Japan from November 1998 to February 1999.

Tan Ching (談慶), male, aged 61, is our independent non-executive Director. Mr. Tan was appointed as our independent non-executive Director on January 25, 2024. Mr. Tan has over 36 years of experience in technology industry, investment and management. His previous working experience includes: serving as (i) a manager in Shenzhen Electronics Group Co., Ltd. (深圳市賽格集團有限公司) from September 1988 to September 1992; (ii) an engineering manager in GE Healthcare U.S. of General Electric Company (a company listed on the New York Stock Exchange under the stock code of GE) from September 1994 to September 1999; (iii) an investment manager in Qifeng Fund (啟峰創投) from February 2000 to January 2001; (iv) a manager in Booz Allen Hamilton from January 2001 to March 2002; (v) a Vice President and General Manager of core imaging in GE Healthcare China of General Electric Company from March 2002 to December 2006; and (vi) director, General Manager and Chief Representative of China in Siguler Guff &

Co., LLC from December 2006 to October 2012. In addition, Mr. Tan has served as (i) the general manager of Shanghai Jiachen Private Equity Fund Management Co., Ltd. (上海甲辰私募基金管理有限公司) since November 2012; (ii) a director of Power MED Limited (能金有限公司) since December 2014; (iii) a supervisor of Beijing Biomarker Technologies Co., Ltd. (北京百邁客生物科技有限公司) from June 2015 to December 2025; (iv) an executive director and the general manager of Guangzhou Jinyongji Investment Consulting Co., Ltd. (廣州市金墉基投資諮詢有限公司) since November 2015; (v) an executive director and the general manager of Shanghai Zhenjin Investment Co., Ltd. (上海臻津投資有限公司) since December 2015; (vi) a director of Shenzhen Feisen Technology Co., Ltd. (深圳市菲森科技有限公司) since September 2016; (vii) a director of Biohit Healthcare (Hefei) Co., Ltd. (必歐瀚生物技術(合肥)有限公司) since January 2018; (viii) a non-executive director of Jenscare Scientific Co., Ltd. (寧波健世科技股份有限公司), a company listed on the Hong Kong Stock Exchange under the stock code of 9877, since March 2019; (ix) a director of HuidaGene (Shanghai) Biotechnology Co., Ltd. (輝大(上海)生物科技有限公司) since December 2019; (x) an executive director of Shanghai Jiachen Enterprise Management Consulting Co. Ltd. (上海迦辰企業管理諮詢有限公司) since July 2020; (xi) a director of Hangzhou Jieyi Biotechnology Co., Ltd. (杭州傑毅生物技術有限公司) since January 2021; (xii) an executive director of Shanghai Fichen Investment Management Co., Ltd. (上海斐辰投資管理有限公司) since January 2021; (xiii) an executive director and general manager of Shanghai Chenxu Enterprise Management Consulting Co., Ltd. (上海辰續企業管理諮詢有限公司) since August 2021; (xiv) a director of Creative Biosciences (Guangzhou) Co., Ltd. (廣州康立明生物科技股份有限公司) since September 2021; (xv) a director of Hangzhou Ezgene Technology Co., Ltd. (杭州易速微控基因技術有限公司) since January 2022; (xvi) a director of BMC Medical Co., Ltd. (北京瑞邁特醫療科技股份有限公司, formerly known as 北京怡和嘉業醫療科技股份有限公司), a company listed on the Shenzhen Stock Exchange under the stock code of 301367, since September 2018; (xvii) a director of Shanghai Wancheng Biotechnology Co., Ltd. (上海綰塍生物科技有限公司) since January 2022; and (xviii) a director of Shenzhen Congheng Technology Co., Ltd. (深圳市聰衡科技有限公司) since October 2022. Mr. Tan was recognized as (i) a "the Healthcare Investor of the Year (Excellence Ranking List)" (卓悦榜年度醫療健康投資人) by Haoyue Capital (浩悦資本) in March 2020, March 2021, April 2022 and April 2023; (ii) a "Top Ten Elite IVD Investors of the Year" (Top 10年度IVD精英投資人) by Chujie Technology (觸界科技) in December 2021; (iii) a "Top 100 China Investors" (投資界TOP 100投資人) by Zero2IPO Holdings Inc. (清科創業控股有限公司) in August 2022 and July 2023; and (iv) a "Top 100 China's Best Venture Investor of Year 20222023" (2022-2023年度中國最佳創業投資人Top100) by CVCapital (投中資本) in November 2023. Mr. Tan obtained a master's degree in business management from University of Chicago in the U.S. in March 2000.

## II. PERFORMANCE OF DUTIES BY THE INDEPENDENT NON-EXECUTIVE DIRECTORS

In 2025, the Company held 4 Board meetings and 2 general meetings. As independent directors, we attended Board meetings on time and were present at relevant general meetings. In the course of performing our duties on the Board, we seriously reviewed various proposals, exercised our voting rights in a prudent manner, and fulfilled our obligations of diligence and due care as independent directors.

The attendance of the independent non-executive directors is set out below:

| | Number of attendance/meetings | | | | | |
|---|---|---|---|---|---|---|
| Name of Director | Board of Directors | Audit Committee | Remuneration Committee | Nomination Committee | ESG Committee | General Meeting |
| Wang Yang | 4/4 | 2/2 | — | — | 1/1 | 2/2 |
| Zhao Huifang | 4/4 | 2/2 | 1/1 | 1/1 | — | 2/2 |
| Tan Ching | 4/4 | — | 1/1 | 1/1 | — | 2/2 |

During the Reporting Period, the independent Directors of the Company did not raise any objections to the Board resolutions and other non-Board resolutions of the Company for the year.

## III. ON-SITE INSPECTIONS

In 2025, we conducted on-site inspections of the Company, communicated fully with the Company, and understood and guided the work of the Company. We focused on the Company's operating conditions, the construction and implementation of systems such as internal control, and the implementation of resolutions of the Board of Directors. In addition, we maintained close liaison with the Directors, the financial controller, the secretary to the Board of Directors and the relevant staff of the Company, keeping an eye on the impacts of the external environment, the industry situation and the market changes on the Company. We kept abreast of the progress of the Company's various major issues and grasped the Company's operation dynamics in order to safeguard the shareholders' rights and interests effectively.

## IV. PROTECTION OF INVESTORS' RIGHTS AND INTERESTS

In 2025, all independent Directors always adhered to the principles of prudence, diligence and faithfulness, performed their duties as independent directors in accordance with the requirements of the relevant laws and regulations, conducted independent, objective and impartial deliberations on the various proposals of the Board of Directors, exercised all their voting rights

carefully and prudently, and earnestly expressed their pre-approval and independent opinions on the relevant matters. At the same time, we supervised and examined the performance of the Company's Directors and senior management, thereby effectively safeguarding the legitimate rights and interests of all shareholders, in particular minority shareholders.

## V. TRAINING AND LEARNING

Since becoming independent Directors, we have actively studied the latest laws, regulations and various rules, participated in relevant training organized by the Company, stock exchanges and other organizations, to comprehensively understand the governance rules of listed companies, deepen our knowledge and understanding of relevant regulations on protecting the rights and interests of public shareholders, and continuously improve our professional standards, practicing competence and ability to perform our duties. We have effectively safeguarded the legitimate rights and interests of investors, especially minority shareholders, provided better opinions and suggestions for the Company's scientific decision-making and risk prevention, promoted the Company's further standardized operation, contributed to the Company's steady progress, and contributed our efforts to the effective protection of shareholders' rights and interests.

**Xunfei Healthcare Technology Co., Ltd.**
**訊飛醫療科技股份有限公司**
*(A joint stock company incorporated in the People's Republic of China with limited liability)*
**(Stock Code: 2506)**

## NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given that an annual general meeting (the "**Annual General Meeting**") of Xunfei Healthcare Technology Co., Ltd. (the "**Company**") will be convened and held at the Company's Meeting Room, 666 West Wangjiang Road, Shushan District, Hefei, Anhui Province, China on Friday, June 26, 2026 at 9:30 a.m. for the purpose of considering, and if thought fit, passing the following resolutions. Unless the context requires otherwise, capitalized terms used herein shall have the same meanings as those defined in the circular of the Company dated June 5, 2026.

### ORDINARY RESOLUTIONS

1. To consider and approve the resolution on the 2025 work report of the board of directors (the "**Board**") of the Company.

2. To consider and approve the resolution on the 2025 annual report of the Company.

3. To consider and approve the resolution on the application to banks for comprehensive credit lines.

4. To consider and approve the resolution on the 2025 financial settlement report of the Company.

5. To consider and approve the resolution on the 2025 profit distribution plan of the Company.

6. To consider and approve the resolution on the remuneration plan for directors and senior management of the Company for 2026.

7. To consider and approve the resolution on the appointment of Deloitte Touche Tohmatsu as auditor of the Company for 2026, and to authorize the Board to fix its remuneration.

8. To consider and approve the resolution on the uncovered losses amounting to one-third of the total paid-up share capital.

**SPECIAL RESOLUTIONS**

9. To consider and approve the resolution on the guarantees for subsidiaries.

10. To consider and approve the resolution on the amendments to the business scope of the Company and amendments to the Articles of Association.

11. To consider and approve the granting of a general mandate to the Board to issue shares:

"**THAT**:

(a) subject to compliance with the prevailing requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Stock Exchange**") and paragraph (b) below, a general mandate be and is hereby generally and unconditionally given to the directors of the Company to (i) allot, issue and deal with (including sale or transfer of any Treasury Shares) additional ordinary shares in the share capital of the Company, (ii) make or grant offers, agreements and options which might require the exercise of such powers during or after the end of the Relevant Period (as defined below) in accordance with all applicable laws, rules and regulations and the provisions of the Articles of Association, (iii) make any amendments to the Articles of Association in relation to issue of shares and registered capital as it duly thinks necessary, and (iv) take any other necessary actions and proceed with other necessary procedures in order to implement the issue and realize the increase in registered capital;

(b) the aggregate number of shares allotted or agreed conditionally or unconditionally to be allotted (including sale or transfer of any Treasury Shares) by the directors pursuant to the mandate in paragraph (a) above, otherwise than pursuant to:

(i) a Rights Issue (as defined below);

(ii) the exercise of options under a share option scheme of the Company; and

(iii) any scrip dividend scheme or similar arrangement providing for the allotment of shares in lieu of the whole or part of a dividend on shares of the Company in accordance with the articles of association of the Company, shall not exceed 20% of the total number of issued shares (excluding any Treasury

Shares) as at the date of passing of this resolution (subject to adjustment in the case of any consolidation or subdivision of shares of the Company after the date of passing of this resolution); and

(c) for the purposes of this resolution:

"**Relevant Period**" means the period from the passing of this resolution until whichever the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable laws to be held; and

(iii) the date on which the authority set out in this resolution is revoked or varied by a special resolution of the shareholders in a general meeting.

"**Rights Issue**" means an offer of shares open for a period fixed by the directors to holders of shares of the Company or any class thereof on the register on a fixed record date in proportion to their then holdings of such shares or class thereof (subject to such exclusions or other arrangements as the directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of any relevant place or the requirements of any recognized regulatory body or any stock exchange)."

12. To consider and approve a general mandate to the directors of the Company to repurchase H Shares:

"**THAT**:

(a) subject to compliance with the prevailing requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and paragraph (b) below, a general mandate be and is hereby generally and unconditionally given to the directors of the Company to (i) exercise during the Relevant Period (as defined below) all the powers of the Company to repurchase H Shares in accordance with all applicable laws, rules and regulations; (ii) make any amendments to the Articles of Association in relation to the repurchase of shares

and changes in registered capital as it duly thinks necessary; and (iii) take any other necessary actions and proceed with other necessary procedures in order to implement the repurchase and realize the decrease in registered capital;

(b) the total number of H shares of the Company to be repurchased pursuant to the mandate in paragraph (a) above shall not exceed 10% of the total number of issued H shares (excluding any treasury shares) as at the date of passing of this resolution (subject to adjustment in the case of any consolidation or subdivision of shares of the Company after the date of passing of this resolution); and

(c) for the purposes of this resolution:

"**Relevant Period**" means the period from the passing of this resolution until whichever the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable laws to be held; and

(iii) the date on which the authority set out in this resolution is revoked or varied by a special resolution of the shareholders in a general meeting."

By order of the Board
**Xunfei Healthcare Technology Co., Ltd.**
**Dr. Tao Xiaodong**
*Executive Director*

Hong Kong, June 5, 2026

*As at the date hereof, the Board comprises: (i) Dr. Tao Xiaodong as executive Director; (ii) Dr. Liu Qingfeng, Mr. Zhao Zhiwei and Mr. Duan Dawei as non-executive Directors; and (iii) Prof. Wang Yang, Prof. Zhao Huifang and Mr. Tan Ching as independent non-executive Directors.*

*Notes:*

1. All resolutions at the meeting will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). The results of the poll will be published on the websites of Hong Kong Exchanges and Clearing Limited and the Company in accordance with the Listing Rules.

2. Any shareholder of the Company entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and on a poll, vote instead of him/her. A proxy need not be a shareholder of the Company. Every shareholder present in person or by proxy shall be entitled to one vote for each share held by him/her.

3. In order to be valid, the form of proxy, together with the power of attorney or other authority, if any, under which it is signed or a notarized copy of that power of attorney or authority, must be deposited at the Company's H Share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (for H Shareholders) or the Company's head office in the PRC at 4 to 5/F (North Area), No.1 Building, iFLYTEK AI Research and Development Production Base (Phase I), No. 666 Science and Innovation Road, Chengxiqiao Community Services Center, High-tech Zone, Hefei City, Anhui Province, PRC (for Domestic Shareholders) not less than 24 hours before the time appointed for the meeting (i.e. not later than 9:30 a.m. on Thursday, June 25, 2026) or any adjournment thereof. Completion and return of the form of proxy shall not preclude a shareholder of the Company from attending and voting in person at the meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.

4. The record date for determining the entitlement to attend and vote at the Annual General Meeting is Friday, June 26, 2026. For the purpose of determining the identity of the holders of H Shares entitled to attend and vote at the meeting, the register of members of the Company will be closed from Tuesday, June 23, 2026 to Friday, June 26, 2026, both dates inclusive, during which period no transfer of H Shares will be registered. In order to be eligible to attend and vote at the Annual General Meeting, unregistered holders of H Shares of the Company shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company's H Share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration not later than 4:30 p.m. on Monday, June 22, 2026 (Hong Kong time), being the last registration date.

5. All time and dates mentioned in this notice refer to Hong Kong time and dates.